Skip to main content
. 2023 Aug 3;12:e79548. doi: 10.7554/eLife.79548

Appendix 2—table 39. Influences on exploratory choice including WASI scores.

Region=NY Antidiabetic Users by BP: Unmatched Region=NY Antidiabetic Users by BP: Matched
All BP Non-user BP User p-value All BP Non-user BP User p-value
N % N % N % N % N % N %
All Patients 104,691 100.0% 95,162 90.9% 9,529 9.1% 18,912 100.0% 9,456 50.0% 9,456 50.0%
Age
≤20 455 0.4% 454 0.5% 1 0.0% <0.001 2 0.0% 1 0.0% 1 0.0% 1.00
21-40 6,164 5.9% 6,152 6.5% 12 0.1% 25 0.1% 13 0.1% 12 0.1%
41-50 10,440 10.0% 10,363 10.9% 77 0.8% 151 0.8% 75 0.8% 76 0.8%
51-60 24,366 23.3% 23,532 24.7% 834 8.8% 1,665 8.8% 831 8.8% 834 8.8%
61-70 28,819 27.5% 25,939 27.3% 2,880 30.2% 5,741 30.4% 2,870 30.4% 2,871 30.4%
71-80 24,314 23.2% 20,338 21.4% 3,976 41.7% 7,880 41.7% 3,941 41.7% 3,939 41.7%
≥81 10,133 9.7% 8,384 8.8% 1,749 18.4% 3,448 18.2% 1,725 18.2% 1,723 18.2%
Gender
Female 60,470 57.8% 51,884 54.5% 8,586 90.1% <0.001 17,022 90.0% 8,509 90.0% 8,513 90.0% 0.92
Male 44,221 42.2% 43,278 45.5% 943 9.9% 1,890 10.0% 947 10.0% 943 10.0%
Insurance
Commercial 32,100 30.7% 31,172 32.8% 928 9.7% <0.001 1,849 9.8% 924 9.8% 925 9.8% 1.00
Dual 2,193 2.1% 1,693 1.8% 500 5.2% 978 5.2% 490 5.2% 488 5.2%
Medicaid 27,928 26.7% 25,978 27.3% 1,950 20.5% 3,793 20.1% 1,897 20.1% 1,896 20.1%
Medicare 42,470 40.6% 36,319 38.2% 6,151 64.6% 12,292 65.0% 6,145 65.0% 6,147 65.0%
PCP Visit 2019
No 37,109 35.4% 33,894 35.6% 3,215 33.7% <.001 6,363 33.6% 3,182 33.7% 3,181 33.6% 0.99
Yes 67,582 64.6% 61,268 64.4% 6,314 66.3% 12,549 66.4% 6,274 66.3% 6,275 66.4%
Continuous Outcomes
mean SD mean SD mean SD p-value mean SD mean SD mean SD p-value
CCI 1.32 1.79 1.31 1.79 1.46 1.87 <0.001 1.44 1.83 1.44 1.82 1.45 1.84 0.75

BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation.